期刊
LANCET DIGITAL HEALTH
卷 2, 期 12, 页码 E667-E676出版社
ELSEVIER
DOI: 10.1016/S2589-7500(20)30192-8
关键词
-
资金
- National Institute of Aging of the US National Institutes of Health (NIH) [R01AG066707, 3R01AG066707-01S1]
- National Heart, Lung, and Blood Institute of the NIH [R00HL138272]
- VeloSano Pilot Program (Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA)
- Frederick National Laboratory for Cancer Research, NIH [HHSN261200800001E]
- Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research
- US National Science Foundation [1750326, 2027970]
- US Office of Naval Research [N00014-18-1-2585]
- Direct For Computer & Info Scie & Enginr
- Div Of Information & Intelligent Systems [2027970, 1750326] Funding Source: National Science Foundation
Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine offer cutting-edge application of information science to defining disease, medicine, therapeutics, and identifying targets with the least error. In this Review, we introduce guidelines on how to use AI for accelerating drug repurposing or repositioning, for which AI approaches are not just formidable but are also necessary. We discuss how to use AI models in precision medicine, and as an example, how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据